GSK’s Linerixibat Shows Success in Treating Relentless Itch in Late-Stage Trial
Breakthrough in Itch Treatment for Autoimmune Disease GSK (GlaxoSmithKline) announced on Tuesday that its experimental drug, linerixibat, successfully met its primary endpoint in a late-stage trial...